City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
Click here to login to Secure Web Site   (authorized users only)  
  
Search results:  395  Clinical trial(s) found  (Page 1 of 16 )
Results per page: 25 50 100 All 1-25 Trials Jump to page:

The following studies are available for :
COH Protocol Number: 18278

Principal Investigator: Marwan Fakih, MD
Sponsor: Institutional

Title:  Individual Patient Supply of BVD-523 for a Patient (WF) with Colorectal Cancer

COH Protocol Number: 18165

Principal Investigator: David Snyder, MD
Sponsor: Institutional

Title:  Individual Patient Supply of Oral Pacritinib for a Patient (RG) with Thrombocytopenia and Primary Myelofibrosis

COH Protocol Number: 18158 ClinicalTrials.gov Number: NCT03446417

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  A Phase 1 Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of ZN-e4 (KP-673) in Patients With Advanced Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor (EGFR) Mutations

COH Protocol Number: 18151

Principal Investigator: Linda Malkas, PhD
Sponsor: Institutional

Title:  CTSA Grant Proposal Data Gathering

COH Protocol Number: 18141 ClinicalTrials.gov Number: NCT03512756

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  A Phase II Multi-Center Study of SM-88 in Subjects with Pancreatic Cancer Whose Disease Has Progressed or Recurred after/on First Line Chemotherapy

COH Protocol Number: 18137 ClinicalTrials.gov Number: NCT02609776

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer

COH Protocol Number: 18116 ClinicalTrials.gov Number: NCT03410927

Principal Investigator: Sumanta Pal, MD
Sponsor: Industrial

Title:  A Phase 1/2, Open-Label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of TAS0728, an Oral Covalent Binding Inhibitor of HER2, in Subjects with Advanced Solid Tumors with HER2 or HER3 Abnormalities

COH Protocol Number: 18115 ClinicalTrials.gov Number: NCT01901094

Principal Investigator: Lisa Yee, MD
Sponsor: Cooperative Group

Title:  Alliance A011202: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

COH Protocol Number: 18113 ClinicalTrials.gov Number: NCT03414970

Principal Investigator: Lisa Yee, MD
Sponsor: Cooperative Group

Title:  Alliance A221505 Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction

COH Protocol Number: 18108 ClinicalTrials.gov Number: NCT02549937

Principal Investigator: Daneng Li, MD
Sponsor: Industrial

Title:  A Multi-Center, Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sulfatinib in Advanced Solid Tumors, and to Evaluate the Anti-tumor Activity and Safety of Sulfatinib in Patients with Advanced Biliary Tract Cancers (BTC) and in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET)

COH Protocol Number: 18103 ClinicalTrials.gov Number: NCT03571828

Principal Investigator: Leslie Popplewell, MD
Sponsor: Industrial

Title:  A Phase 1, First-in-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With Relapsed / Refractory Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma

COH Protocol Number: 18101 ClinicalTrials.gov Number: NCT03153462

Principal Investigator: L. elizabeth Budde, MD, PhD
Sponsor: Industrial

Title:  A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects With Relapsed/Refractory Large B-cell Lymphoma

COH Protocol Number: 18100 ClinicalTrials.gov Number: NCT03459222

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered in Combination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 inhibitor) or in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

COH Protocol Number: 18090 ClinicalTrials.gov Number: NCT02927249

Principal Investigator: Lisa Yee, MD
Sponsor: Cooperative Group

Title:  Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial

COH Protocol Number: 18083 ClinicalTrials.gov Number: NCT03368859

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  Phase 2 Study Comparing Efficacy and Safety of ABT-165 plus FOLFIRI vs Bevacizumab plus FOLFIRI in Metastatic Colorectal Cancer Previously Treated with Fluoropyrimidine/Oxaliplatin and Bevacizumab

COH Protocol Number: 18082 ClinicalTrials.gov Number: NCT03435796

Principal Investigator: Tanya Siddiqi, MD
Sponsor: Industrial

Title:  Long-Term Follow-Up Protocol For Subjects Treated with Gene-Modified T Cells

COH Protocol Number: 18080

Principal Investigator: Finly Zachariah, MD
Sponsor: NCI Approved External Peer Review

Title:  Comparative Effectiveness of Early Integrated Telehealth versus In-Person Palliative Care for Patients with Advanced Lung Cancer (Short Name: REACH PC)

COH Protocol Number: 18065 ClinicalTrials.gov Number: NCT03007147

Principal Investigator: Weili Sun, MD, PhD
Sponsor: Cooperative Group

Title:  COG AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones

COH Protocol Number: 18058 ClinicalTrials.gov Number: NCT03189030

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Phase 1 Safety and Tolerability Study of Personalized Live, Attenuated, Double-Deleted Listeria monocytogenes (pLADD) Immunotherapy in Adults with Metastatic Colorectal Cancer

COH Protocol Number: 18056 ClinicalTrials.gov Number: NCT03406949

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Phase 1, Open Label, Dose Escalation Study of MGD009, a Humanized B7-H3 x CD3 DART® Protein, in Combination with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory B7-H3-Expressing Tumors

COH Protocol Number: 18051 ClinicalTrials.gov Number: NCT03041688

Principal Investigator: Amandeep Salhotra, MD
Sponsor: NCI Approved External Peer Review

Title:  PHI-92, NCI#10075: A Phase 1B Study of AMG-232 in Combination with Decitabine in Acute Myeloid Leukemia

COH Protocol Number: 18044

Principal Investigator: Victoria Seewaldt, MD
Sponsor: Institutional

Title:  Reducing Cancer and Chronic Disease Risk in Underserved Communities: Eat, Move, Live Community Program

COH Protocol Number: 18040 ClinicalTrials.gov Number: NCT03321643

Principal Investigator: Alex Herrera, MD
Sponsor: NCI Approved External Peer Review

Title:  PHI-96, NCI#10126: A Pilot Phase I Study of Atezolizumab (MPDL3280A) in Combination with Immunogenic Chemotherapy (Gemcitabine-Oxaliplatin) and Rituximab for Transformed Diffuse Large B-Cell Lymphoma

COH Protocol Number: 18030 ClinicalTrials.gov Number: NCT03258554

Principal Investigator: Sagus Sampath, MD
Sponsor: Cooperative Group

Title:  NRG Oncology NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin

COH Protocol Number: 18029 ClinicalTrials.gov Number: NCT03556228

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects with Solid Tumors or Lymphoma

 
Results per page: 25 50 100 All 1-25 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.